Literature DB >> 9430467

Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer.

H Minn1, M Lapela, P J Klemi, R Grénman, S Leskinen, P Lindholm, J Bergman, E Eronen, M Haaparanta, H Joensuu.   

Abstract

UNLABELLED: The aim of this prospective study was to investigate if high uptake of 18F-fluoro-2-deoxy-D-glucose (FDG) is associated with aggressiveness in head and neck cancer and low probability of survival.
METHODS: Thirty-seven patients with squamous-cell carcinoma of the head and neck underwent FDG-PET in the fasting state before cancer treatment. FDG uptake in primary tumor was quantitated as the standardized uptake value of FDG normalized to the predicted lean body mass (SUVlean, n = 37) and as the graphically determined metabolic rate for FDG (rMR[FDG], n = 34). Paraffin-embedded tumor samples were used for histologic evaluation, and expression of cytokeratin and Ki-67 antigen were assessed by immunohistochemistry.
RESULTS: Interobserver agreement for the determination of quantitative uptake of FDG in tumors was excellent (r2 = 0.996, p < 0.00001), and all 37 primary tumors were visualized. A high uptake of FDG as assessed by SUVlean was associated with a higher than the median mitotic count (p = 0.01), absence of keratinization (p = 0.03), low or moderate histological grade of differentiation (p = 0.046) and advanced stage (p = 0.03), but not with Ki-67 expression (p = 0.11). The overall survival of patients with a SUVlean lower than or equal to the median value (9.0) was clearly better in univariate analysis than that of patients with a SUVlean higher than the median (3-yr survival 73% versus 22%, relative risk of death (RR) 4.2, 1.6-11.0). However, in a multivariate analysis the only independent predictors of survival were the mitotic count (RR 4.0, 1.4-11.7) and stage (3.8, 1.2-12.2).
CONCLUSION: High uptake of FDG in untreated head and neck cancer is associated with advanced disease, and may portend poor survival. Aggressive treatment approaches should be considered for patients presenting with a tumor with high uptake of FDG.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9430467

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  59 in total

1.  Predictive value of fluorodeoxyglucose uptake in head and neck cancer: importance of standardization: editorial on EAORL-D-10-00277.

Authors:  Remco de Bree; Otto S Hoekstra
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-08-04       Impact factor: 2.503

2.  Diffusion weighted imaging in predicting progression free survival in patients with squamous cell carcinomas of the head and neck treated with induction chemotherapy.

Authors:  Su Berrak; Sanjeev Chawla; Sungheon Kim; Harry Quon; Eric Sherman; Laurie A Loevner; Harish Poptani
Journal:  Acad Radiol       Date:  2011-08-10       Impact factor: 3.173

3.  Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes.

Authors:  Karen P Chu; James D Murphy; Trang H La; Trevor E Krakow; Andrei Iagaru; Edward E Graves; Annie Hsu; Peter G Maxim; Billy Loo; Daniel T Chang; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-21       Impact factor: 7.038

4.  Prospective imaging assessment of mortality risk after head-and-neck radiotherapy.

Authors:  Benjamin J Moeller; Vishal Rana; Blake A Cannon; Michelle D Williams; Erich M Sturgis; Lawrence E Ginsberg; Homer A Macapinlac; J Jack Lee; K Kian Ang; K S Clifford Chao; Gregory M Chronowski; Steven J Frank; William H Morrison; David I Rosenthal; Randal S Weber; Adam S Garden; Scott M Lippman; David L Schwartz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-18       Impact factor: 7.038

5.  Use of pretreatment metabolic tumour volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy.

Authors:  Chia-Hung Kao; Shih-Chieh Lin; Te-Chun Hsieh; Kuo-Yang Yen; Shih-Neng Yang; Yao-Ching Wang; Ji-An Liang; Chun-Hung Hua; Shang-Wen Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-25       Impact factor: 9.236

6.  Prognostic value of preoperative 18F-FDG PET/CT for primary head and neck squamous cell carcinoma.

Authors:  Young-Hoon Joo; Ie-Ryung Yoo; Kwang-Jae Cho; Jun-Ook Park; In-Chul Nam; Chung-Soo Kim; Min-Sik Kim
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-08-15       Impact factor: 2.503

7.  Functional imaging to predict treatment response after (chemo) radiotherapy of head and neck squamous cell carcinoma.

Authors:  Remco de Bree
Journal:  Quant Imaging Med Surg       Date:  2013-10

Review 8.  Glucose deprivation-induced metabolic oxidative stress and cancer therapy.

Authors:  Andrean L Simons; David M Mattson; Ken Dornfeld; Douglas R Spitz
Journal:  J Cancer Res Ther       Date:  2009-09       Impact factor: 1.805

9.  Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma.

Authors:  Jonathan H Lee; Seza A Gulec; Ainura Kyshtoobayeva; Myung-Shin Sim; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2009-07-15       Impact factor: 5.344

10.  Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study.

Authors:  Mei Tian; Hong Zhang; Yoshiki Nakasone; Kenji Mogi; Keigo Endo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.